AcceGen

Agendia is a precision oncology company headquartered in Irvine, California, committed to bringing patients with early stage breast cancer and their physicians the information they need to make the best decisions for the full treatment journey. The company currently offers two commercially-available genomic profiling tests, supported by the highest levels of clinical and real world evidence, that provide comprehensive genomic information that can be used to identify the most effective breast cancer treatment possible for each patient.

MammaPrint®, the 70-gene breast cancer recurrence assay, is the only FDA-cleared risk of recurrence test backed by peer-reviewed, prospective outcome data and inclusion in both national and international treatment guidelines. BluePrint®, the 80-gene molecular subtyping assay, is the only commercially-available test that evaluates the underlying biology of a tumor to determine what is driving its growth. Together, MammaPrint® and BluePrint® provide a comprehensive genomic profile to help physicians make more informed decisions in the pre- and post-operative treatment settings.

Agendia develops evidence-based novel genomic tests and forges partnerships with groundbreaking companies to develop next-generation digital treatment tools. The ongoing research builds an arsenal of data that improve patient outcomes and support the evolving clinical needs of patients with breast cancer and their physicians every step of the way, from initial diagnosis to cancer-free.

Agendia’s assays can be ordered on core biopsies or surgical specimens to inform pre- and post-operative treatment decisions. For more information on Agendia’s assays and ongoing trials, please visit www.agendia.com.

For view our social media policies, please visit https://agendia.com/legal-compliance/

APExBIO Technology LLC is a premier provider of Small Molecule Inhibitors/Activators, Compound Libraries, Peptides, Assay Kits, Fluorescent Probes, Enzymes, Modified Nucleotides, mRNA synthesis and various tools for Molecular Biology. We carry a broad product line in over 20 different research areas such as cancer, immunology, neurosciences, apoptosis and epigenetics etc. Based in USA (Houston, Texas), we have been serving the needs of customers across the world.

Qualities
We pay the most careful attention to the quality of our products. All products are manufactured with rigorous guidelines and are accompanied with certificates of analysis, HPLC, Mass Spectrum, and HMNR, as well as in vitro validation. APExBIO products have been cited by many top peer-reviewed journals such as Nature, Cell and Science.

Services
Biologists and Chemists at APExBIO offer extensive tech support to our customers for using the products. You may expect personalized and attentive care from our support staff answering your order and technical inquiries. We also provide custom services including peptide synthesis, custom mRNA synthesis and assay development.

Since our inception in January of 2006, Assay Biotechnology has been a worldwide contributor of industry-leading antibody and assay technologies, fluorescent dyes, quenchers, recombinant proteins and synthetic peptides. Located in the heart of California’s San Francisco Bay Area, we have strived to answer the global need for high quality assay kits and immunological reagents used in academic and pharmaceutical research that formulate the basis of healthcare.

For the first couple years after our founding, Assay Biotech established itself as an antibody manufacturer, catering specifically to large corporations through OEM partnerships. Since then, we have been emerging as a prominent assay and antibody source, expanding our reach to millions of researchers in over 50 countries around the world. We are determined to become one of the world’s leading assay development and manufacturing companies, providing a multitude of ready-to-use assays, immunological reagents, molecular detection modules and biomarkers to support the most arduous academic and pharmaceutical research endeavors.

Bio-Techne Corporation (NASDAQ: TECH) is a leading developer and manufacturer of high-quality purified proteins and reagent solutions - notably cytokines and growth factors, antibodies, immunoassays, biologically active small molecule compounds, tissue culture reagents, and cell and gene therapy workflow solutions including T-Cell activation technologies. Bio-Techne’s portfolio also includes protein analysis solutions, sold under the ProteinSimple brand name, that offer researchers efficient and streamlined options for automated Western blot and multiplexed ELISA workflow. These reagent and protein analysis solutions are sold to biomedical researchers, as well as clinical research laboratories, and constitute the Protein Sciences Segment.

Bio-Techne also develops and manufactures diagnostic products including FDA-regulated controls, calibrators, blood gas and clinical chemistry controls, and other reagents for OEM and clinical customers. Bio-Techne’s genomic tools include advanced tissue-based in situ hybridization assays (ISH) for research and clinical use, sold under the ACD brand, as well as a portfolio of clinical molecular diagnostic oncology assays including the ExoDx®Prostate (IntelliScore) test (EPI) for prostate cancer diagnosis. These diagnostic and genomic products comprise Bio-Techne’s Diagnostics and Genomics Segment.

Bio-Techne products are integral components of scientific investigations into biological processes and molecular diagnostics, revealing the nature, diagnosis, etiology and progression of specific diseases. They aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. With thousands of products in its portfolio, Bio-Techne generated approximately $714 million in net sales in fiscal 2019 and has over 2,200 employees worldwide.

Bioauxilium is a private Canadian biotechnology company founded by seasoned scientists from PerkinElmer. The company is focused on the design, development and manufacturing of top-quality, fully-validated assay kits that simplify laboratory workflow and accelerate biomedical research.
Since its inception in 2013, Bioauxilium has licensed hundreds of TR FRET assay kits enabling the quantification of cellular proteins and biomarkers. Bioauxilium’s kits are based on its proprietary THUNDER™ TR-FRET technology. They are offered at an outstanding value and are supported by expert technical support. Bioauxilium also provides on a contract basis customized services in assay development using diverse cutting-edge technologies.

Our services:
■ Custom TR-FRET-based immunoassay kit development and manufacturing
■ Conversion of ELISAs into homogeneous immunoassays (TR-FRET, AlphaLISA) amenable to automation using your antibody pair or our “best pair” screening service
■ Custom labeling: labeling of biomolecules with lanthanides, fluorophores or biotin to build reagent tools necessary for assay development
■ Custom biochemical, cell-based and biomarker assay development using multiple technology platforms (absorbance, fluorescence, FP, TRF, TR-FRET, luminescence, AlphaScreen, AlphaLISA)
■ Assay design, development, optimization and validation for drug discovery research, from HTS to lead optimization